title: Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014.
abstract: Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resistance to standard chemotherapy regimens. Emerging developmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occurring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population.
authors: Weill-Cornell/New York Presbyterian Hospital, New York, NY. Electronic address: efeldman@seagen.com.
authors: Eric J
authors: EJ
authors: Feldman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
keywords: New treatment of secondary AML